Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group
Year: 2025
Type: article
Study design: Clinical Trial
Abstract: Developing new therapeutic regimens for relapsed/refractory (R/R) B non-Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti-CD20-containing immunochemotherapy regimen. We report here the final analysis of the phase II LYSA-promoted multicentre trial (NCT03276468) of this combination in follicular lymphoma (FL, n = 58), diffuse large B-cell lymphoma (DLBCL, n = 58) and marginal zone lymphoma (MZL, n = 20). The primary end-point for FL and DLBCL was not met: ATE, OBI, and VEN resulted in an overall response rate (ORR) at the end of induction (EOI) of 53.6% for FL (cohort 1) and 23.6% for DLBCL (cohort 2) when a minimum of 70% and 48% was expected respectively. The median progression-free survival was 11.0 and 2.7 months in cohorts 1 and 2 respectively. In cohort 3 (MZL), the ORR at the EOI was evaluated at 66.7%. The most frequent adverse events (AEs) were cytopenias. We also observed 7.4% of autoimmune AE imputable to the combination. In this phase II study, ATE, OBI and VEN demonstrated moderate efficacy and a manageable toxicity profile when used as induction and maintenance therapy.
Source: British Journal of Haematology
DOI: 10.1111/bjh.20109
Authors: Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Pierre Feugier, Gandhi Damaj, Hervé Tilly, Loïc Ysebaert, Steven Le Gouill, Nadine Morineau, Emmanuel Gyan, Rémy Gressin, Roch Houot, Morgane Cheminant, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Emmanuelle Nicolas‐Virelizier, Luc‐Matthieu Fornecker, Nicolas Daguindau, Guillaume Cartron
Institutions: Centre National de la Recherche Scientifique, Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, Institut de Génétique Moléculaire de Montpellier, Institut de Génétique Humaine, Hôpital Lyon Sud, Institut Paoli-Calmettes, Centre Hospitalier Universitaire de Poitiers, CHU Dijon Bourgogne, Centre Hospitalier Régional et Universitaire de Nancy, Centre Hospitalier Universitaire de Caen Normandie, Centre Henri Becquerel, Institut universitaire du cancer de Toulouse Oncopole, Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Laboratoire d'imagerie translationnelle en oncologie, Institut Curie, Centre Hospitalier Départemental Vendée, Université de Tours, Centre Hospitalier Universitaire de Tours, Centre Hospitalier Universitaire de Grenoble, Université Grenoble Alpes, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Hôpital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Hôpital Saint-Louis, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, Centre Léon Bérard, Centre Hospitalier Annecy Genevois
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Funder: Roche
OpenAlex ID: W4409829575